Pharmaceutical Information |
Drug Name |
Rizatriptan |
Drug ID |
BADD_D01957 |
Description |
Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist. |
Indications and Usage |
For treatment of acute migraine attacks with or without aura. |
Marketing Status |
approved |
ATC Code |
N02CC04 |
DrugBank ID |
DB00953
|
KEGG ID |
D08485
|
MeSH ID |
C093622
|
PubChem ID |
5078
|
TTD Drug ID |
D0S9MU
|
NDC Product Code |
33342-088; 71335-1352; 62938-0020; 65977-0067; 33342-087; 63850-7138; 63850-7119 |
UNII |
51086HBW8G
|
Synonyms |
rizatriptan | N,N-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1H-indole-3-yl)ethylamine | rizatriptan benzoate | MK 0462 | MK-0462 | MK-462 | MK 462 | L 705,126 | L-705,126 | L-705126 | L 705126 | Maxalt |
|
Chemical Information |
Molecular Formula |
C15H19N5 |
CAS Registry Number |
144034-80-0 |
SMILES |
CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3 |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|